NMD4C Hire New Communications Coordinator
New Communications Coordinator
The NMD4C are pleased to announce the hiring of their new communications coordinator, James Davis.
James holds a Masters degree in Human Kinetics, and holds previous network creation experience. Through his efforts to help build a national Sport Safety framework, James has a skillset well-suited to the role. He also has research experience from his time at Cochrane. While there he worked on systematic reviews of literature to aid in health policy development.
Communications Coordinator Role
As one of two dedicated NMD4C staff members, James writes and coordinates all network communications. This includes news updates, monthly newsletter, website, and social media (Twitter, Facebook, and LinkedIn). He also manages membership and will liaise with the many people and sites involved in the network.
Contact James
If you are looking for more information, check out James’ bio! Here you can find his contact information. If you have any communications-related inquiries, please send James a message!
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.